fda warning letters bpc-157 compounding letter unapproved new drug The U.S. Food and Drug Administration is moving toward allowing pharmacies to produce more than a dozen injectable peptides that were banned Partnership for Safe Medicines urges
Description
Stable pentadecapeptide derived from a gastric protein, studied for tendon healing, angiogenesis and gut integrity

[2] If symptoms are severe or persistent, it's important to discuss them with your healthcare professional

Use of BPC-157 occurs outside approved regulatory frameworks, either as part of research protocols or through compounding pharmacies and research chemical suppliers
Some of the human trials involved injecting the peptide under the skin (subcutaneously) and into the muscles (intramuscularly)
